Share This

Public company info - Transcenta Holding Limited , 06628.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Transcenta Holding Limited, 06628.HK - Company Profile
Chairman Yining (Jonathan) Zhao
Share Issued (share) 445,000,000
Par Currency U.S. Dollar
Par Value 1.0E-4
Industry Biotechnology
Corporate Profile Business Summary: The group is a clinical stage biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. Performance for the year: The group’s loss and total comprehensive expenses for the year were RMB437.6 million and RMB319.5 million for the years ended December 31, 2019 and 2020, respectively. Business Review The group’s management team and the key operations, including clinical development, regulatory access and business development are based both in China and the United States, whereas the group’s discovery, research and development, process development and manufacturing teams are based in China. the group adopt a global approach to maximize operational efficiency. Concurrently, the group leverage the efficient regulatory approval pathway to accelerate the Investigational New Drug (IND) applications and early-phase clinical trials in the United States and to advance clinical trials in the indications with significant unmet medical needs from the large patient population in China. the group design trials that allow clinical data from each trial to be used for pooled analysis and for supporting registration, including China, the United States and countries in Europe. In addition, clinical data from multi-regional clinical trials will enable future indication expansion for the drug(s) investigated in the countries and regions where the group plan for. The group have developed a unique antibody discovery platform, the Immune Tolerance Breaking (IMTB) technology platform, which enables us to generate antibodies to both non-conserved and conserved proteins that are difficult to generate in rodents and to discover hidden epitopes that are challenging to discover by using conventional platforms. the group’s IMTB technology platform allows us to obtain lead candidate antibodies with expanded epitope diversity, differentiated biological properties (specificity, affinity and pharmacokinetics) and desirable CMC (chemistry, manufacturing and controls) profiles, resulting in selecting candidate molecules with enhanced druggability attributes and strong intellectual property position. Leveraging this IMTB technology platform, the group have generated TST001, which targets a conserved epitope on Claudin 18.2, and MSB2311, an antibody targeting programmed death-ligand 1 (PD-L1), a type of protein that controls immune responses, and binding to an epitope that conferred MSB2311 with pH-dependent antigen binding property. Furthermore, the group established a translational research team that is capable of (i) conducting an IHC-based protein expression analysis of the drug target protein in both human and animal tissue samples of various disease models or cell lines; (ii) conducting studies to evaluate the in vivo disease intervention activities of the investigational agents using tumor models grown in mouse or models of bone and kidney diseases; and (iii) analyzing the pharmacokinetics and pharmacodynamics profile of the investigational agents. the group’s translational research team enables us to model tumor responses to the group’s investigational agents and to better understand pharmacokinetics/pharmacodynamics (PK/PD) profiles, which guides design and conduct of clinical study and evaluates the options of combination therapy with agents targeting different signaling disease pathways. the group also have a platform that allows us to screen antibodies for target-detection using immunohistochemistry and to develop immunohistochemistry detection assay for patient selection in clinical trials, which allows us to maximize potential trial success by enrolling patients with a high probability of responding to the drug treatment in selected indications. The group’s discovery and global development capabilities have enabled us to build diversified pipeline of innovative and promising antibodies in therapeutic areas with unmet medical needs including oncology, nephrology and bone diseases. As of the Latest Practicable Date, the group have discovered and developed eight of nine drug candidates in-house, covering both validated, partially validated and novel biological pathways. In particular, the group have one core product: MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; and four key drug candidates: TST001, a humanized Claudin 18.2 mAb candidate for solid tumors such as gastric cancer; TST005, a PD-L1/TGF- (transforming growth factor beta is a multipotent growth factor affecting cell differentiation, proliferation, apoptosis and matrix production) bi-functional antibody candidate for solid tumors including certain lung cancers; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized MASP-2 (mannan-binding lectin serine protease 2, an indispensable enzyme for the activation of the lectin pathway of complement) mAb candidate for IgA kidney diseases. In addition to the above drug candidates, The group is also developing a number of early-stage innovative biotherapeutic candidates. For example, The group is developing TST003, a potentially the first therapeutic antibody candidate around the world targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype. In addition, the group have developed TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor (TACI) protein, which has the potential for the treatment of autoimmune disease such as systemic lupus erythematosus (SLE). The group’s CMC function is capable of developing efficient manufacturing processes to support speed to clinical trial and speed to market while ensuring products meet regulatory requirements and are safe, efficacious and consistent between batches throughout product life cycle. the group have established a modular GMP (good manufacturing practice) facility, T-BLOC, in Hangzhou, which has two 500L and one 2,000L single use bioreactor and two downstream purification trains. This highly flexible facility supports both fed-batch and continuous perfusion processes with an overall projected annual capacity of over one metric ton (1,000 kg). To increase productivity of conventional fed-batch processes, the group have implemented intensified fed-batch processes (high seeding cell density using perfusion seed bioreactor), in which the group have demonstrated increases in process output by greater than 100% over conventional fed-batch processes. To maximize facility output with significant lower cost of goods, improve process robustness and minimize operational risks, The group is developing and implementing a continuous manufacturing platform called Integrated Continuous Bioprocessing (ICB), where a proprietary and highly productive continuous upstream perfusion process will be integrated with an automated and continuous downstream process that The group is co-developing with Merck. By leveraging the power of ultra-high cell density continuous perfusion process and the group’s proprietary cell culture media, the group have demonstrated industry leading volumetric productivities of over 6 g/L-day and output increases for multiple cell lines of up to 10 to 20-fold when compared to conventional fed-batch processes. As of the Latest Practicable Date, the group have successfully implemented continuous upstream perfusion process into GMP manufacturing for TST005 and will also apply to TST001 in the second quarter of 2021. According to the CIC Report, The group is one of the only three companies in China that has implemented continuous perfusion process for GMP clinical supply. This platform can also enhance the control of product quality and can produce both stable and less stable antibodies such as some multi-specific antibodies or novel protein formats, which facilitates standardization of biomanufacturing. The group’s core management team members have an average of greater than 15 years of industry experience with proven track record and a well-balanced combination of expertise spanning research, clinical development, manufacturing, planning and financing. the group’s shareholders consist of global and Chinese biotechnology-focused specialist funds and biopharmaceutical platforms experienced in supporting and growing biopharmaceutical companies. Therefore, the group benefit from their resources and industry expertise. As of the Latest Practicable Date, in relation to the group’s core product, the group owned one issued patent in each of China, the United States, Macau and Hong Kong, one pending patent application in each of China and the United States and seven pending patent applications in other jurisdictions. As of the Latest Practicable Date, in relation to the group’s key products, the group owned three PCT priority applications, one pending PCT application and one pending patent application in Taiwan, and co-owned one PCT priority application with the group’s collaborator, Beijing Cancer Hospital. In addition, the group also in-licensed one issued Chinese patent in relation to TST002. Prospects: To realize the group’s vision to deliver high quality and affordable innovative biologics to patients around the world, the group will pursue the following strategies: • Rapidly advance the group’s oncology franchise through clinical development • Accelerate the development of the group’s other IND-enabling and pre-clinical drug candidates • Enhance the group’s pipeline through in-house discovery and business development efforts • Maximize the global value of the group’s drug candidates • Expand the group’s manufacturing facilities to support the group’s upcoming and expanding pipeline • Continue strengthening the group’s commercialization capabilities

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.